ProMRI Phase B

ProMRI

Phase B

Clinical Safety of the ProMRI Pacemaker System when Used Under Specific MRI Conditions without Scan Exclusion zone.

Link to Download Section

Study Design

  • Prospective, single-arm, non-ramdomized, multicenter

SADE free rate

99.6% free of MRI and pacing system related serious adverse device effects1

Atrial pacing threshold

100% of patients experienced

Ventricular pacing threshold

100% of patients experienced < 0.5 V ventricular pacing threshold increase post-MRI1

Clinical Relevance

  • Data demonstrates and supports the clinical safety and efficacy of the ProMRI pacemaker system when used under specific MRI conditons
Reference no.
  • NCT02009696
Study Objective
  • The objective of the ProMRI study is to demonstrate the clinical safety of the ProMRI pacemaker system when used under specific MRI conditions.
1° Endpoints
  • MRI and pacing system related serious adverse device effect (SADE) free rate
  • Percentage of participants free of atrial pacing threshold rise
  • Percentage of participants free of ventricular pacing threshold rise
  • Percentage of participants free of P-wave sensing attenuation
  • Percentage of participants free of R-wave sensing attenuation
Clinical Sites
  • 31 US Centers
Sample Size
  • 245
Main Inclusion Criteria
  • Patients implanted with a pacemaker system consisting only of an Entovis pacemaker (DR-T, SR-T) and one or two Setrox S 53 or Setrox S 60 pacemaker lead(s)
  • Patients with measureable pacing thresholds greater than or equal to 2.0 V @ 0.4 ms
  • Patients with pacemakers implanted at least 6 weeks prior to MRI procedure
Main Exclusion Criteria
  • Patients implanted with other medical devices that may interact with MRI
Devices
  • Entovis pacemaker (DR-T, SR-T) and one or two Setrox S 53 or Setrox S 60 pacemaker lead(s)
Follow-Up
  • Three months post-MRI
Study Duration
  • December 2013 - January 2015

Download Section

Open access to the publication
Tachycardia Therapy

TACHYCARDIA THERAPY

More Information

BIOTRONIK offers an extensive product portfolio in the area of tachycardia therapy.

  1. Bailey WM, Mazur A, McCotter C, Woodard PK, Rosenthal L, Johnson W, Mela T; ProMRI Study Investigators. Clinical safety of the ProMRI pacemaker system in patients subjected to thoracic spine and cardiac 1.5-T magnetic resonance imaging scanning conditions. Heart Rhythm. 2016 Feb;13(2):464-71. doi: 10.1016/j.hrthm.2015.09.021. Epub 2015 Sep 25.